Search Results for "donepezil"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for donepezil. Results 1 to 10 of 15 total matches.
See also: Aricept

Donepezil (Aricept) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 1997  (Issue 1002)
Donepezil (Aricept) for Alzheimer's Disease ...
Donepezil hydrochloride (Aricept - Eisai), a piperidine-based acetylcholinesterase inhibitor, is now being marketed for oral treatment of cognitive symptoms in patients with mild to moderate dementia due to Alzheimer's disease. Donepezil is the second drug approved for this indication; tacrine hydrochloride (Cognex), also an acetylcholinesterase inhibitor, has been available in the USA for four years (Medical Letter, 35:87, 1993).
Med Lett Drugs Ther. 1997 Jun 6;39(1002):53-4 |  Show IntroductionHide Introduction

A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only) ...
A once-weekly transdermal formulation of the acetylcholinesterase inhibitor donepezil (Adlarity – Corium) has been approved by the FDA for treatment of mild, moderate, and severe Alzheimer's disease (AD) dementia. Donepezil is the second acetylcholinesterase inhibitor to become available in a transdermal formulation; transdermal rivastigmine (Exelon Patch), which is applied once daily, has been available for years for the same indication. Donepezil is also available in oral formulations (Aricept, and generics) for treatment of AD dementia.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):e128-9 |  Show IntroductionHide Introduction

Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
combination of extended-release (ER) memantine (Namenda XR), an NMDA-receptor antagonist, and donepezil ...
The FDA has approved Namzaric (Forest), a fixed-dose combination of extended-release (ER) memantine (Namenda XR), an NMDA-receptor antagonist, and donepezil (Aricept, and generics), an acetylcholinesterase inhibitor, for treatment of moderate to severe Alzheimer's type dementia in patients previously stabilized on both drugs. The patent for Namenda has recently expired and generic formulations of memantine 5- and 10-mg tablets have been approved.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):105-6 |  Show IntroductionHide Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
.2 Donepezil, galantamine, and rivastigmine are FDA approved for treatment of AD dementia based ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 |  Show IntroductionHide Introduction

Rivastigmine (Exelon) For Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
for this indication; tacrine hydrochloride (Cognex) and donepezil hydrochloride (Aricept) are also available (Medical ...
Rivastigmine tartrate (Exelon - Novartis), a carbamate-based cholinesterase inhibitor, is now being marketed for treatment of patients with dementia due to Alzheimer's disease.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):93-4 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
Effects Drug Interactions Comments Acetylcholinesterase Inhibitors Donepezil – generic Aricept (Eisai ...
View the Comparison Table: Drugs for Alzheimer's Disease
Med Lett Drugs Ther. 2022 Aug 22;64(1657):e136-7 |  Show IntroductionHide Introduction

Galantamine (Reminyl) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
INHIBITORS FOR ALZHEIMER’S DISEASE Drug Dosage Cost* Donepezil − Aricept (Pfizer) 5 or 10 mg once/day ...
Galantamine hydrobromide (Reminyl), a tertiary alkaloid and phenanthrene derivative extracted from daffodil bulbs, is now being marketed for oral treatment of mild to moderate Alzheimer's disease. Galantamine is the fourth acetylcholinesterase inhibitor approved for this indication.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):53-4 |  Show IntroductionHide Introduction

Table: Mechanisms of Drug Interactions (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
penetration of the aminoglycoside Antagonism Opioid + naloxone Donepezil + an anticholinergic Competitive ...
View Table: Mechanisms of Drug Interactions
Med Lett Drugs Ther. 2018 Sep 24;60(1556):e160 |  Show IntroductionHide Introduction

Memantine for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003  (Issue 1165)
inhibitors donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and tacrine (Cognex ...
Memantine hydrochloride, which has been used to treat dementia in Germany (Axura Merz) since 1982, has become the latest word-of-mouth miracle drug for Alzheimer's disease in the US (G Kolata, NY Times, June 15, 2003). Forest Laboratories has submitted a New Drug Application to the FDA for memantine. This review describes the standard treatment for Alzheimer's Disease, mechanism of action, clinical studies, adverse effects and dosage. Also included are sections on availability of the drug and how some people are obtaining memantine from abroad.
Med Lett Drugs Ther. 2003 Sep 15;45(1165):73-4 |  Show IntroductionHide Introduction

Aducanumab (Aduhelm) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021  (Issue 1628)
— The acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine and the NMDA-receptor antagonist memantine ...
Aducanumab-avwa (Aduhelm – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The approval was based on the surrogate endpoint of reduction in amyloid beta plaques in the brain. The manufacturer is required to conduct an additional randomized controlled trial to establish that reducing amyloid beta plaques with aducanumab improves clinical outcomes in patients with Alzheimer's disease.
Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-6 |  Show IntroductionHide Introduction